Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    SAFC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 781

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Artificial intelligence (AI) is emerging as a transformative force in drug discovery and development. The global AI in drug discovery market was valued at US$ 1.99 billion in 2024 and is estimated to reach US$ 2.65 billion in 2025. Going forward, the market is expected to grow at an impressive compounded annual growth rate (CAGR) of 29.6 percent, to reach a market size of US$ 35.42 billion by 2034, says a report by Polaris Market Research. This growth expectation mirrors the eagerness within the biopharma industry to leverage AI in order to overcome the traditional barriers of lengthy timelines, exorbitant costs, and high failure rates. This eagerness is also being manifested in deal making — Big Pharma has been busy forging alliances with AI-driven drug discovery companies. Over the last two years, almost every big drugmaker, including Novo Nordisk, Merck, BMS, Pfizer, AstraZeneca, Otsuka Pharmaceutical, Novartis and Sanofi, has signed deals with various AI drug discovery companies. PharmaCompass' compilation shows there are scores of molecules discovered by AI currently in discovery and developmental phases, demonstrating the technology's growing impact on pharmaceutical pipelines.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available) Novo, Lilly, BMS invest in AI partnerships; Recursion, Exscientia merge to create AI powerhouse With the transformative potential of AI becoming increasingly evident, we witnessed a slew of deals in the biopharma industry over the last six months. A significant deal in the AI drug discovery space was the merger of two leaders — Recursion and Exscientia — that took place in November last year. Exscientia is now a wholly-owned subsidiary of Recursion. The merger has created a global technology-enabled drug discovery leader with end-to-end capabilities. The merged entity has over 10 clinical and preclinical programs, and around 10 advanced discovery programs in the pipeline.  Apart from this merger, several large drugmakers have struck deals with AI drug discovery firms since September last year. For instance, in January this year, Valo Health and Novo Nordisk expanded their collaboration to discover and develop novel treatments for cardiometabolic diseases. This deal, valued at up to US$ 4.8 billion, aims to harness the power of AI and extensive human datasets. Building on their initial 2023 partnership, it will enable the development of up to 20 drug programs.  Similarly, Pfizer, which is already big on AI, extended its AI drug discovery pact with PostEra and also partnered IgnitionAI to enhance drug discovery — all within the last six months. And Novartis struck a drug discovery deal with Generate BioMedicines in September. Insilico Medicine has been actively forging partnerships. In January, Insilico entered a second exclusive global license agreement with Menarini Group for an AI-discovered preclinical asset targeting high unmet needs in oncology. Insilico also has a tie-up with Sanofi, dating back to 2022. In December 2024, AI Proteins announced a research collaboration and option agreement with BMS to design and optimize mini-proteins for therapeutic use. And in September, Eli Lilly joined hands with Genetic Leap to accelerate the development of genetic medicines. Lilly will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against selected targets.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  AI leads to faster target identification; Insilico, BenevolentAI’s candidates in trials Computational biology, and especially AI, has fundamentally changed the drug discovery paradigm. The traditional method of drug discovery used to take 13 to 15 years, costing an average of US$ 2.5 billion in investment before a drug got approved and launched in the market. Additionally, less than 10 percent of candidates in phase 1 clinical trials used to end up getting approved by the US Food and Drug Administration (FDA). All that has begun to change. According to Khair ElZarrad, Director of the Office of Medical Policy within FDA’s Center for Drug Evaluation and Research, since 2016, FDA has received approximately 300 submissions that reference AI use as of May 2024. These submissions range from drug development, drug discovery, clinical research, clinical trials as well as post-market safety surveillance and manufacturing. Though we are yet to witness an AI-generated candidate translate into an approved therapy, target identification in drug discovery is visibly becoming a lot faster. This is the process that identifies specific molecules or pathways in the human body that are linked to a disease. The best example of dramatic acceleration of timelines is Insilico Medicine’s development of INS018_055, a candidate for idiopathic pulmonary fibrosis that entered phase 2 trials in June 2023. Using their AI platform PandaOmics, researchers at Insilico compressed target identification from years to just 18 months. Similarly, BenevolentAI successfully employed their AI platform to identify a new target for ulcerative colitis, leading to the development of BEN-8744, a candidate that has been in phase 1a clinical trials since August 2023.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Oncology leads AI drug discovery market; Recursion shows how to repurpose drugs using AI The integration of AI in oncology research has been impactful, accounting for the largest revenue share (about 22.4 percent) in the AI drug discovery market in 2023. AI technologies have accelerated the discovery and development of new cancer treatments, bolstered personalized medicine approaches, and improved clinical trial designs in the arena of this complex disease.  Another promising application is drug repurposing, where AI can identify new therapeutic applications for existing drugs. Recursion Pharmaceuticals’ REC-2282 exemplifies this approach. This therapy is currently in phase 2/3 studies for neurofibromatosis type 2 (a genetic condition that causes tumors to grow along nerves). By repurposing compounds already vetted for safety, this strategy can bypass early-stage failures, reducing both time and cost compared to developing entirely new molecules. However, the use of AI in drug discovery is not without challenges. Exscientia’s EXS-21546, designed to treat solid tumors, entered phase 1/2 trials in 2020 but was discontinued in 2023 after modeling suggested that achieving a suitable therapeutic index would be difficult. Though this is a clinical failure, it highlights AI’s value in identifying potential failures earlier on in the development process, saving resources that would have otherwise been spent on later-stage trials.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Our view The Covid-19 pandemic was a time when humanity felt the urgent need to speed up the process of drug discovery, testing and approvals. It also hastened the process of integrating AI into pharmaceutical research, leading to the launch of Covid vaccines in record time. Today, there is no looking back — AI is bringing about a paradigm shift in how drugs are discovered. With increasing reliance on AI, there is hope that drug discovery will be more accurate, efficient and less time and cost consuming.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1286

    https://www.pharmacompass.com/radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals

    #PharmaFlow by PHARMACOMPASS
    13 Mar 2025
    Share Share

    NEWS #PharmaBuzz

    [Sponsored by another company]read-more
    read-more
    Merck unveils EU plant cuts and consolidation plan citing Sigma's US strategy
    Merck unveils EU plant cuts and consolidation plan citing Sigma's US strategy

    14 Jul 2017

    // G. MacDonald IN PHARMATECHNOLOGIST

    http://www.in-pharmatechnologist.com/Processing/German-Merck-announces-EU-plant-cuts-and-consolidation-plan

    G. MacDonald IN PHARMATECHNOLOGIST
    14 Jul 2017
    Share Share
    EC says Merck and Sigma-Aldrich broke M&A procedures and could face $170m fine
    EC says Merck and Sigma-Aldrich broke M&A procedures and could face $170m fine

    07 Jul 2017

    // G. MacDonald IN PHARMATECHNOLOGIST

    http://www.in-pharmatechnologist.com/Processing/EC-says-Merck-and-Sigma-Aldrich-broke-M-A-procedures

    G. MacDonald IN PHARMATECHNOLOGIST
    07 Jul 2017
    Share Share
    Improving solubility: MilliporeSigma opens dedicated meglumine site
    Improving solubility: MilliporeSigma opens dedicated meglumine site

    19 Jan 2017

    // Dan Stanton IN PHARMATECHNOLOGIST

    http://www.in-pharmatechnologist.com/Ingredients/Improving-solubility-MilliporeSigma-opens-dedicated-meglumine-site

    Dan Stanton IN PHARMATECHNOLOGIST
    19 Jan 2017
    Share Share
    MilliporeSigma Expands Distribution Agreement with Roche in Canada
    MilliporeSigma Expands Distribution Agreement with Roche in Canada

    01 Dec 2016

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/milliporesigma-expands-distribution-agreement-with-roche-in-canada-300367603.html

    PR NEWSWIRE
    01 Dec 2016
    Share Share
    Honeywell Launces New Research Chemicals Business
    Honeywell Launces New Research Chemicals Business

    29 Nov 2016

    // DRUG DEVELOPMENT

    http://www.drug-dev.com/Main/Current-News/Honeywell-Launces-New-Research-Chemicals-Business-1770.aspx

    DRUG DEVELOPMENT
    29 Nov 2016
    Share Share
    Merck's pharma unit faces tougher 2017 as fertility boost recedes
    Merck's pharma unit faces tougher 2017 as fertility boost recedes

    17 Nov 2016

    // Phil Taylor PMLIVE

    http://www.pmlive.com/pharma_news/mercks_pharma_unit_faces_tougher_2017_as_fertility_boost_recedes_1176998

    Phil Taylor PMLIVE
    17 Nov 2016
    Share Share
    Contact Safc and get a quotation

    Safc is a supplier offers 204 products (APIs, Excipients or Intermediates).

    Find a price of Benzyl Alcohol API bulk with DMF, CEP offered by Safc

    Find a price of Clomipramine Hydrochloride bulk with DMF, CEP offered by Safc

    Find a price of Dactinomycin bulk with DMF, JDMF offered by Safc

    Find a price of Doxylamine Succinate bulk with DMF, CEP offered by Safc

    Find a price of L-Glutamine bulk with DMF, JDMF offered by Safc

    Find a price of Sodium Benzoate bulk with DMF, CEP offered by Safc

    Find a price of L-Glutamine bulk with JDMF offered by Safc

    Find a price of Sodium Bicarbonate bulk with JDMF offered by Safc

    Find a price of Aprotinin bulk with CEP offered by Safc

    Find a price of Bovine Serum bulk with CEP offered by Safc

    Find a price of Brompheniramine Maleate bulk with DMF offered by Safc

    Find a price of Catalase bulk with CEP offered by Safc

    Find a price of Cholic Acid bulk with DMF offered by Safc

    Find a price of Chymotrypsin bulk with CEP offered by Safc

    Find a price of Dodecyl Maltoside bulk with DMF offered by Safc

    Find a price of DPPC bulk with DMF offered by Safc

    Find a price of Ethanol bulk with DMF offered by Safc

    Find a price of Glucarpidase bulk with CEP offered by Safc

    Find a price of Glucose bulk with JDMF offered by Safc

    Find a price of Glycine bulk with DMF offered by Safc

    Find a price of Hyaluronidase bulk offered by Safc

    Find a price of L-Carnosine bulk with CEP offered by Safc

    Find a price of L-Glutamine bulk with DMF offered by Safc

    Find a price of L-Tyrosine API bulk with JDMF offered by Safc

    Find a price of Levothyroxine Sodium bulk with DMF offered by Safc

    Find a price of Lysine Hydrochloride bulk with DMF offered by Safc

    Find a price of Maytansinoid DM1 bulk with DMF offered by Safc

    Find a price of Mebrofenin bulk with DMF offered by Safc

    Find a price of Nortriptyline bulk with DMF offered by Safc

    Find a price of Palmitic Acid Chloride bulk with DMF offered by Safc

    Find a price of Sodium Metaarsenite bulk with DMF offered by Safc

    Find a price of Sulfo-Smcc bulk with DMF offered by Safc

    Find a price of Tripalmitin bulk with DMF offered by Safc

    Find a price of Trypan Blue bulk with DMF offered by Safc

    Find a price of Urea API bulk with DMF offered by Safc

    Find a price of Vitamin D bulk with DMF offered by Safc

    Find a price of EX-CELL PF CHO MEDIUM (MODIFIED) DEFICIENT bulk with DMF offered by Safc

    Find a price of EX-CELL CD HEK293 VIRAL VECTOR MEDIUM bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60258 CHOKO PRODUCTION MEDIUM POWDER bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60259, CHOKO STOCK CULTURE MEDIUM POWDER bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60274 bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60229 bulk with DMF offered by Safc

    Find a price of MAYTANSINOL-N-METHYL-L-ALANYL ESTER bulk with DMF offered by Safc

    Find a price of EX-CELL PF CHO PART A (MODIFIED) bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60256 CHOKO FMA POWDER bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM 14366C bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60273 bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR40118 bulk with DMF offered by Safc

    Find a price of EX-CELL(TM) 325 PF CHO, SERUM-FREE MEDIUM, PROTEIN FREE bulk with DMF offered by Safc

    Find a price of QBSF60 MEDIUM PRODUCT NO. 62520 bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60257, CHOKO FMB POWDER bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60275 bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60219 bulk with DMF offered by Safc

    Find a price of CELL CULTURE MEDIUM CR60234 bulk with DMF offered by Safc

    Find a price of Media/Medium Additives・EX-CELL EBx PRO-I Serum-Free Media bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · Fatty Acid Supplement bulk with JDMF offered by Safc

    Find a price of Medium/medium additive ・R36 Low B12 bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives-EX-CELL Advanced CHO Feed 1 (without glucose) bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive ・ CHOKO Production Medium Powerer bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · CHO Feed Bioreactor Supplement bulk with JDMF offered by Safc

    Find a price of Medium/Medium additives・EX-CELL(R) Basal Medium bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives ・ CHOKO Stock Culture Medium Powerer bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · EX-CELL 325 PF CHO Serum-Fr ee Medium for CHO Cells bulk with JDMF offered by Safc

    Find a price of Medium/medium additive R7A-1 bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives-EX-CELL (TM) CD Hydrolysate Fusion Animal Coordinate Free, Chemically Defined bulk with JDMF offered by Safc

    Find a price of Medium/Medium additives/GM BI 221 Feed Powder bulk with JDMF offered by Safc

    Find a price of Medium/medium additive R17 bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive ・ IMF9-2X bulk with JDMF offered by Safc

    Find a price of Medium/Medium additives/GM BI 215 Medium Powder bulk with JDMF offered by Safc

    Find a price of Medium/medium additive ・F48 Low B12 no HC bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive / IMF8 bulk with JDMF offered by Safc

    Find a price of Culture medium/Culture additives: EX-CELL® Advanced CHO Fed-batch Medium bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · Sigma EX-CELL 302 Serum-Fr ee Medium for CHO Cells bulk with JDMF offered by Safc

    Find a price of Medium/Medium Additives・EX-CELL EBx PRO-I Serum-Free Medium for Embryonic Stem Cells bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · EX-CELL EBx PRO-Ⅰ Serum-Fre e Medium for Embryonic Stem Cells bulk with JDMF offered by Safc

    Find a price of Media/Media Additives GS2-N Low B12 No Hydrocort bulk with JDMF offered by Safc

    Find a price of Medium/medium additive EX-CELL (R) 293 Serum-Free Medium for HEK 293 Cells bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives-EX-CELL ACF CHO Medium bulk with JDMF offered by Safc

    Find a price of Culture medium/Culture additives・EX-CELL EBx GRO-I Serum-Free Media bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives ・ CHOKO FMB Powerer bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives ・ CHOKO FMA Powerer bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · EX-CELL EBx PRO-Ⅰ Serum-Fre e Media bulk with JDMF offered by Safc

    Find a price of Medium/Medium additives・EX-CELL(R) Feed Medium bulk with JDMF offered by Safc

    Find a price of Medium/medium additive ・R34B Medium bulk with JDMF offered by Safc

    Find a price of Medium / media supplements · EX-CELL (TM) 325 PF CHO Protei n-Free Medium (Modified) bulk with JDMF offered by Safc

    Find a price of Medium/medium additive ・Trace Element B Solution B (1000X) bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive ・ TE1 bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive / IMB9 bulk with JDMF offered by Safc

    Find a price of Medium/Medium additives/GM BI 203 Medium Powder bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive / IMB8 bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · Sigma EX-CELL PF CHO Mediu m (Modified) bulk with JDMF offered by Safc

    Find a price of Medium/Medium Additives・Ex-CELL EBx GRO-I Serum-Free Medium for Embryonic Stem Cells bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · Ex-CELL EBx GRO-Ⅰ Serum-Fre e Medium for Embryonic Stem Cells bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives-EX-CELL Advanced (TM) Modified bulk with JDMF offered by Safc

    Find a price of Medium/Medium additives・40X Insect Cell Feed bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives ・ CHO Kit 2 Iron Chelator Solution bulk with JDMF offered by Safc

    Find a price of Deoxyribonuclease I, Desoxyribonuclease I Crude Lyophilized Powder, Product Number D0876/DN25 and Desoxyribonuclease I Type II, Product Number D4527 bulk with CEP offered by Safc

    Find a price of Medium / medium additive · EX-CELL EBx GRO-Ⅰ Serum-Fre e Media bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · StemlineⅡ Hematopoietic Stem C ell Expansion Medium bulk with JDMF offered by Safc

    Find a price of Media/Media Additives ・Trace Element E 1000X Solution bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additive / PER2 bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives-SuppAA-1 bulk with JDMF offered by Safc

    Find a price of Medium / Medium Additives-EX-CELL Advanced CHO Feed 1 bulk with JDMF offered by Safc

    Find a price of Medium / medium additive · C8862: EX-CELL CHO DHFR\n- Medium bulk with JDMF offered by Safc

    Find a price of 3-5-Diiodothyropropionic Acid bulk offered by Safc

    Find a price of 3-Amino-3-3-Chlorophenyl-Propanoic Acid bulk offered by Safc

    Find a price of Ammonium Tetrathiomolybdate bulk offered by Safc

    Find a price of Armodafinil bulk offered by Safc

    Find a price of Bovine Insulin bulk offered by Safc

    Find a price of Bovine Serum bulk offered by Safc

    Find a price of Calcipotriol bulk offered by Safc

    Find a price of Calcitriol bulk offered by Safc

    Find a price of Camptothecine bulk offered by Safc

    Find a price of Carbamazepine bulk offered by Safc

    Find a price of Cetyl Alcohol API bulk offered by Safc

    Find a price of Cholesterol-3,4-13C2 bulk offered by Safc

    Find a price of Copper bulk offered by Safc

    Find a price of Cortisol-9,11,12,12-D4 bulk offered by Safc

    Find a price of Dextrans bulk offered by Safc

    Find a price of Fenbendazole bulk offered by Safc

    Find a price of Galactomannan bulk offered by Safc

    Find a price of Gentisic Acid bulk offered by Safc

    Find a price of GUANIDINE HYDROCHLORIDE API bulk offered by Safc

    Find a price of Halobetasol bulk offered by Safc

    Find a price of Halofuginone Lactate bulk offered by Safc

    Find a price of Hexadimethrine Bromide bulk offered by Safc

    Find a price of Homotaurine bulk offered by Safc

    Find a price of Hydroxydopamine Hydrobromide bulk offered by Safc

    Find a price of Iron bulk offered by Safc

    Find a price of Isobutylmethylxanthine bulk offered by Safc

    Find a price of Isobutyramide bulk offered by Safc

    Find a price of Isosulfan Blue bulk offered by Safc

    Find a price of L-Carnosine bulk offered by Safc

    Find a price of L-Glutamine bulk offered by Safc

    Find a price of Mafodotin [Usan] bulk offered by Safc

    Find a price of Mebrofenin bulk offered by Safc

    Find a price of Mechlorethamine bulk offered by Safc

    Find a price of Methacetin-13C bulk offered by Safc

    Find a price of Methyl Tert-Butyl Ether bulk offered by Safc

    Find a price of Methylformamide bulk offered by Safc

    Find a price of Pefcalcitol bulk offered by Safc

    Find a price of Penicillamine bulk offered by Safc

    Find a price of Pentamidine Isethionate bulk offered by Safc

    Find a price of Percorten bulk offered by Safc

    Find a price of Polygalacturonic Acid bulk offered by Safc

    Find a price of Promethazine Hydrochloride bulk offered by Safc

    Find a price of Putrescine Hydrochloride bulk offered by Safc

    Find a price of Rhodamine 123 bulk offered by Safc

    Find a price of Sodium Bicarbonate bulk offered by Safc

    Find a price of Sodium Butyrate bulk offered by Safc

    Find a price of Sodium Metaarsenite bulk offered by Safc

    Find a price of Sodium Octanoate-1-13C bulk offered by Safc

    Find a price of Squalene API bulk offered by Safc

    Find a price of Thrombin bulk offered by Safc

    Find a price of Trypan Blue bulk offered by Safc

    Find a price of Vitamin D3 bulk offered by Safc

    Find a price of EX-CELL 400 bulk offered by Safc

    Find a price of HEMOCYANIN FROM KEYHOLE LIMPET bulk offered by Safc

    Find a price of STEMLINE NEURAL STEM CELL EXPANSION MEDIUM bulk offered by Safc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN WISCONSIN. bulk offered by Safc

    Find a price of 93% DME (HG)/5% NCTC (CAT. NO. 52-589) bulk offered by Safc

    Find a price of EX-CELL(TM) 302, CHO, SERUM-FREE MEDIUM(MODIFIED) bulk offered by Safc

    Find a price of 9-AMINO-1,2,3,4,-TETRAHYDROCRIDINE HCL. (THA) bulk offered by Safc

    Find a price of CHO ANIMAL-FREE MEDIUM MODIFICATION 21 bulk offered by Safc

    Find a price of SGD-1006 (SG6) bulk offered by Safc

    Find a price of EX-CELL(TM) 325 PF CHO PROTEIN-FREE MEDIUM (MODIFIED) bulk offered by Safc

    Find a price of STEMMAX(TM), PRODUCT NO. 62647 bulk offered by Safc

    Find a price of 2-METHOXYESTRA-3,17 B-DIOL bulk offered by Safc

    Find a price of EX-CELL PF CHO MEDIUM(MODIFIED) bulk offered by Safc

    Find a price of EX-CELL 301 COMPLETE MEDIUM (MODIFIED) bulk offered by Safc

    Find a price of 62180 bulk offered by Safc

    Find a price of EX-CELL 301 bulk offered by Safc

    Find a price of STEMLINE™ MESENCHYMAL STEM CELL EXPANSION MEDIUM bulk offered by Safc

    Find a price of SERUM-FREE MEDIA SUPPLEMENT PART A (100 X) bulk offered by Safc

    Find a price of ISCOVE'S MODIFIED DULBECCO'S MEDIUM (IMDM) bulk offered by Safc

    Find a price of DMS-12 (100X) CONCENTRATE bulk offered by Safc

    Find a price of Q1196-9 bulk offered by Safc

    Find a price of STEMLINE(TM) II HEMATOPOIETIC STEM CELL EXPANSION MEDIUM bulk offered by Safc

    Find a price of EX-CELLr ANTIFOAM GAMMA IRRADIATED BY SER-TAINr PROCESS bulk offered by Safc

    Find a price of CHO MEDIUM-ANIMAL COMPONENT-FREE bulk offered by Safc

    Find a price of EX-CELL 302 MEDIUM (MODIFIED) CAT. #62630 bulk offered by Safc

    Find a price of EX-CELL 325 PF CHO (MODIFIED) PRODUCT NO. 63131 bulk offered by Safc

    Find a price of EX-CELL PF CHO MEDIUM (MODIFIED) CATALOG NO. 67480 bulk offered by Safc

    Find a price of EX-CELL 610 HSF HYBRIDOMA, SERUM-FREE MEDUIM. CATALOG NO. 14610 bulk offered by Safc

    Find a price of EX-CELL 325 PF CHO PROTEIN FREE MEDIUM bulk offered by Safc

    Find a price of EX-CELL 525 FOR PER C6 CELLS, DEFINED SERUM FREE MEDIUM bulk offered by Safc

    Find a price of PEG TELOMER B bulk offered by Safc

    Find a price of 67210 bulk offered by Safc

    Find a price of STEMLINE(TM) DENDRITIC CELL MATURATION MEDIUM bulk offered by Safc

    Find a price of PF-11 bulk offered by Safc

    Find a price of CHO MEDIUM MODIFICATION 21 bulk offered by Safc

    Find a price of EX-CELL (TM) 293 MEDIUM bulk offered by Safc

    Find a price of EX-CELL(TM) 302, MEDIUM, SERUM-FREE MEDIUM bulk offered by Safc

    Find a price of BIOTAIN-MPS TM CONCENTRATE (100X) bulk offered by Safc

    Find a price of 1(2PHENYLETHYL)4(N(2PYRAZYL)2(FUROYLAMIDO)PIPERIDINE HCl bulk offered by Safc

    Find a price of EX-CELL(TM) 302, CHO, SERUM-FREE MEDIUM bulk offered by Safc

    Find a price of EX-CELL CD HYDROLYSATE FUSION, ANIMAL COMPONENT FREE, CHEMICALLY-DEFINED LIQUID MEDIA, (PRODUCT NO. 14700C), DRY POWDER MEDIA (PRODUCT NO. 24700C) bulk offered by Safc

    Find a price of EX-CELL (TM) VPRO bulk offered by Safc

    Find a price of ROSE BENGAL, DISODIUM SALT, SIGMA-ALDRICH CHEMICAL CO. PRODUCT NUMBER W184-3 bulk offered by Safc

    Find a price of EX-CELL 302 MEDIUM (GS MODIFIED), CATALOG NO. 62639 bulk offered by Safc

    Find a price of EX-CELL PF CHO MEDUIM (MODIFIED), CATALOG NO. 62625 bulk offered by Safc

    Find a price of EX-CELL PF CHO MEDIUM (MODIFIED) DEFINED SERUM-FREE MEDIUM bulk offered by Safc

    Find a price of EX-CELL PF CHO bulk offered by Safc

    Find a price of PHOSPHATE BUFFERED SALINE (PRODUCT 62137) bulk offered by Safc